Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Avecho Biotechnology Limited ( (AU:AVE) ) has issued an update.
Avecho Biotechnology Limited has reported progress in its Phase III clinical trial of a TPM-enhanced CBD capsule for treating insomnia, marking a significant milestone for the company. The trial, which has begun dosing patients, encountered slower recruitment due to stringent criteria but is set to accelerate in 2025 with revised criteria and additional trial sites. This development positions Avecho to potentially achieve a significant industry milestone and has opened up substantial partnership opportunities. Additionally, Avecho has completed a major manufacturing campaign for its U.S. partner, Ashland, producing Vital-ET for the global personal care market. The company also reported financial investments in R&D and received a loan from Endpoints Capital, closing the year with a notable cash balance.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is a company that develops and commercializes innovative human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). This system, derived from Vitamin E, enhances the solubility and absorption of drugs and nutrients, both orally and through the skin. Avecho is focused on delivering TPM® enhanced injectable, oral, and topical products for the human health market and is also working on applications for livestock feed efficiency and health.
Current Market Cap: A$9.51M
Learn more about AVE stock on TipRanks’ Stock Analysis page.
